Zymeworks Inc Stock News

Upgrades SVB Leerink upgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Underperform to Market Perform. Moderna earned $5.24 in the second quarter, compared to $6.46 in the year-ago quart

Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down

Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down

U.S. stocks closed lower on Wednesday, with the Dow Jones dropping 100 points. Here is the list of some big stocks recording gains in the previous session. Amprius Technologies, Inc. (NYSE: AMPX) jum

Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of E

Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share. Scopus BioPharma Inc. (NASDAQ:

Investors applauded a major licensing deal with Jazz Pharmaceuticals.

Investors applauded a major licensing deal with Jazz Pharmaceuticals.

Zymeworks (NYSE: ZYME ) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ ). This agreement has Jazz Pharmaceuticals acquirin

Shares of Zymeworks Inc. ZYME, -2.43% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -0.41% for its cancer drug, zanidat

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,

Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52. IMARA Inc. (NASDAQ: IMRA) shares climbed 46.9% to close

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 375 points on Friday. The Dow traded down 1.25% to 29,662.76 while the NASDAQ fell 2.68% to 10,363.83. The S&P 50